Mersana Announces Second Quarter 2017 Financial Results and Provides Business Updates
- Successfully Completed Initial Public Offering Raising
$75 Millionin Gross Proceeds
- Phase 1 Trial of XMT-1522 Continues Enrollment of Patients with Advanced Tumors Expressing HER2
“In this quarter, we achieved an important milestone with the successful completion of our initial public offering, raising
Platform and Pipeline Highlights
XMT-1522: XMT-1522 is a Dolaflexin-based HER2-targeted ADC targeting tumors not addressed by currently approved HER2 therapies.
- Enrollment of the Phase 1 dose escalation study of XMT-1522 continues in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer with interim safety results expected around the end of 2017.
June 2017, Mersana presented a Trials in Progressabstract on Phase 1 trial design of its lead program, XMT-1522, a novel HER2-targeted ADC, at the 2017 American Society of Clinical Oncology( ASCO) annual meeting in Chicago, IL.
April 2017, at the American Association for Cancer Research(AACR) Annual Meeting, Mersana presented preclinical data on the biodistribution of XMT-1522 in mice carrying HER2-expressing tumors, providing in vivo proof-of-concept of Mersana’s proprietary DolaLock payload technology. In this study, there was exposure to both the primary ADC payload release product and its active metabolite in the tumor for two weeks after a single dose of XMT-1522, with minimal exposure to either payload in normal tissues. The results presented support the potential of Mersana’s Dolaflexin ADC platform to provide a greater therapeutic index by simultaneously improving efficacy via greater payload delivery and tolerability through the DolaLock payload technology.
- Also at the AACR Annual Meeting in
April 2017, Mersana presented preclinical data supporting the activity of XMT-1522 as monotherapy and in combination with immune checkpoint inhibitors in NSCLC models. We believe these data support the enrollment of NSCLC patients in the XMT-1522 early development program and its potential synergistic effect with checkpoint inhibitors.
XMT-1536: XMT-1536 is a potential first-in-class Dolaflexin ADC targeting NaPi2b-expressing tumors.
- The Phase 1 study of XMT-1536, a potential first in class NaPi2b ADC, remains on track for initiation of clinical trials in early 2018, with the in-life portion of the Good Laboratory Practice (GLP) toxicology studies now successfully completed.
Recent Corporate Highlights
July 2017, Mersana completed its initial public offering, raising approximately $75.0 millionin gross proceeds through the sale of 5,000,000 shares of its common stock at an offering price of $15.00per share.
Second Quarter 2017 Financial Results
- Cash, cash equivalents and marketable securities as of
June 30, 2017were $77.2 million, compared with $100.3 millionas of December 31, 2016. Cash, cash equivalents and marketable securities as of June 30, 2017did not include net proceeds of approximately $67.5 millionfrom the Company's initial public offering, as described above. The Company expects that its cash, cash equivalents and marketable securities will enable it to fund its operating plan through at least mid-2019.
- Research and development expenses for the quarter were approximately
$10.6 million, compared to $8.2 millionfor the same period in 2016. The increase was primarily due to additional personnel and external costs associated with continued clinical development of the Company’s lead program XMT-1522 and IND-enabling studies and manufacturing activities associated with its second program, XMT-1536, which is expected to enter clinical development in early 2018.
- General and administrative expenses for the quarter were approximately
$2.2 million, compared to $1.8 millionfor the same period in 2016. The increase was primarily due to additional personnel expense as the Company builds the infrastructure to support the growth of research and development organization and increased professional fees as the Company prepared to operate as a publicly traded company.
- Net loss for the quarter was
$8.9 million, or $6.33per share, compared to a net loss of $3.8 million, or $3.00per share, for the same period in 2016.
About the Dolaflexin Platform
Mersana’s lead platform, Dolaflexin, is designed to increase the potency and efficacy of ADCs while simultaneously increasing the safety and tolerability. The backbone of Dolaflexin is Fleximer®, a biodegradable, biocompatible, highly water soluble polymer, to which are attached multiple molecules of Mersana’s proprietary auristatin drug payload. Because of the excellent physicochemical properties provided by the polymer, ADCs can be created with drug-antibody ratios of 12-15, significantly higher than what is achieved with traditional ADC approaches. More drugs per antibody results has resulted in preclinical trials in more efficient payload delivery to the tumor cell, particularly for targets with low expression levels, leading to greater potency and efficacy. In addition, Mersana’s proprietary auristatin payload contained in Dolaflexin has been designed with DolaLock technology, a controlled bystander effect, thereby increasing tolerability. The initial release product upon internalization of the ADC is a form of auristatin which is freely cell permeable and can kill adjacent cells. However, a metabolic “trigger” has been incorporated into the auristatin payload such that as it diffuses in the tumor environment it is converted into a highly active payload, which is no longer freely cell permeable, resulting in its becoming “locked” into the cell in which it is formed, thereby increasing tolerability.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the possible or assumed timing of the Company’s clinical trials, business strategies and financing plans.
Forward-looking statements generally can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Forward-looking statements represent management’s beliefs and assumptions only as of the date of this presentation. The Company’s operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Company’s results of operations include, among other things, that preclinical testing may not be predictive of the results or success of ongoing or later preclinical or clinical trials and that the development of the Company’s product candidates will take longer and/or cost more than planned, as well as those listed in the Company’s Prospectus filed on
Copies of the Company’s Prospectus and other
Selected Condensed Consolidated Balance Sheet Data
|June 30, 2017||December 31, 2016|
|Cash, cash equivalents and marketable securities (1)||$||77,232||$||100,297|
|Working capital (2)||48,134||73,787|
|Convertible preferred stock||94,450||94,450|
|Total stockholders' deficit||(71,655||)||(55,619||)|
|(1) Cash, cash equivalents and marketable securities as of June 30, 2017 did not include net
proceeds of approximately $67.5 million from the Company's initial public offering of its
common stock, which was completed in July 2017.
|(2) The Company defines working capital as current assets less current liabilities. See the
Company's condensed consolidated financial statements for further detail regarding its current
assets and current liabilities.
Condensed Consolidated Statement of Operations
(in thousands, except share and per share data)
|Three months ended||Six months ended|
|June 30, 2017||June 30, 2016||June 30, 2017||June 30, 2016|
|Research and development||10,627||8,171||20,733||15,607|
|General and administrative||2,204||1,826||4,501||3,447|
|Total operating expenses||12,831||9,997||25,234||19,054|
|Net loss per share attributable
to common stockholders —
basic and diluted
|Weighted-average number of
common shares used in net
loss per share attributable to
common stockholders —
basic and diluted
Contacts Media Contact
Mersana Therapeutics, Inc. Paul Kidwell, 617-680-1088 firstname.lastname@example.org or Investors Contact Stern Investor Relations, Inc. Christina Tartaglia, 212-362-1200 email@example.com